Literature DB >> 1134883

Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion.

G Levy, N N Khanna, D M Soda, O Tsuzuki, L Stern.   

Abstract

The purpose of this study was to determine if certain physiologic parameters (plasma bilirubin concentration and urinary excretion rate of D-glucaric acid) can be used to predict a newborn infant's ability to eliminate a phenolic drug, and particularly to predict the ability to conjugate that drug with glucuronic acid. Tweleve healthy 2- to 3-day-old full-term infants with plasma bilirubin concentrations of 1.0 to 11.6 mg/100 ml and D-glucaric acid excretion rates of 0.131 to 0.345 mg/kg/day received a single oral dose of acetaminophen, 12 mg/kg. Urine was collected serially for 48 hours and analyzed for acetaminophen, acetaminophen glucuronide, acetaminophen sulfate, and D-glucaric acid. The biologic half-life of acetaminophen was 3.5 plus or minus 0.85 hours (average plus or minus SD) as compared to average values of 1.9 to 2.2 hours observed in five reported studies on a total of 39 adults. The rate constant for acetaminophen glucuronide formation in neonates was considerably smaller, on the average, than in adults but the average rate constant for acetaminophen sulfate formation was somewhat larger than in adults. There is not statistically significant colucaric acid excretion. The results of this study suggest that the limited ability of neonates to conjugate phenolic drugs with glucuronic acid is compensated to a degree by a well-developed capability for sulfate conjugation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1134883

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  49 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children.

Authors:  B J Anderson; G A Woollard; N H Holford
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

3.  Pharmacokinetics of paracetamol after cardiac surgery.

Authors:  C S Hopkins; S Underhill; P D Booker
Journal:  Arch Dis Child       Date:  1990-09       Impact factor: 3.791

4.  Perspectives on the history and scientific contributions of Gerhard Levy.

Authors:  Ho-Leung Fung; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-24       Impact factor: 2.745

5.  alpha-Methyldopa, alpha-methyldopamine an alpha-methylnoradrenaline: substrates for the thermolabile form of human platelet phenol sulphotransferase.

Authors:  G Mwaluko; R Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

6.  Passage of paracetamol into breast milk and its subsequent metabolism by the neonate.

Authors:  L J Notarianni; H G Oldham; P N Bennett
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

Review 7.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. I. Lignocaine.

Authors:  G W Mihaly; R G Moore; J Thomas; E J Triggs; D Thomas; C A Shanks
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

9.  Prenatal exposure to acetaminophen and asthma in children.

Authors:  Elizabeth M Kang; Lisbet S Lundsberg; Jessica L Illuzzi; Michael B Bracken
Journal:  Obstet Gynecol       Date:  2009-12       Impact factor: 7.661

10.  Does rapid metabolism ensure negligible risk from bisphenol A?

Authors:  Gary Ginsberg; Deborah C Rice
Journal:  Environ Health Perspect       Date:  2009-07-14       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.